Literature DB >> 2360815

Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects.

R M Stroshane1, M H Silverman, R Sauerschell, R R Brown, A W Boddy, J A Cook.   

Abstract

Amifloxacin pharmacokinetics after a single oral dose in healthy elderly subjects were determined. Five males and five females aged 65 to 79 years and having creatinine clearances of 39.3 to 87.2 ml/h per kg of body weight were given a 200-mg amifloxacin caplet following an overnight fast. Mean (standard deviation) pharmacokinetic parameters for amifloxacin were as follows: maximum observed concentration in plasma, 1.13 (0.48) and 1.95 (0.52) micrograms/ml; half-life, 5.37 (0.96) and 4.47 (0.87) h; total plasma clearance (unadjusted for fraction absorbed), 259 (53) and 199 (55) ml/h per kg; renal clearance, 113 (20) and 86 (26) ml/h per kg; Varea/F (Varea is volume of distribution; F is fraction absorbed), 2.05 (0.75) and 1.28 (0.39) liter/kg; and amifloxacin excreted in the urine, 42.5% (14.5%) and 42.8% (10.6%) for males and females, respectively. There were no statistically significant differences in pharmacokinetic parameters between sexes that could not be attributed to differences in body weight. Except for a modest 23% reduction in renal clearance and the suggestion of reduced bioavailability, mean values of pharmacokinetic parameters for elderly male subjects were similar to those previously determined for younger male volunteers. Therefore, a modification in amifloxacin dosage regimen based solely on age may not be necessary.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2360815      PMCID: PMC171685          DOI: 10.1128/AAC.34.5.751

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Pharmacokinetics of ciprofloxacin in elderly subjects.

Authors:  M LeBel; G Barbeau; M G Bergeron; D Roy; F Vallée
Journal:  Pharmacotherapy       Date:  1986 Mar-Apr       Impact factor: 4.705

2.  Pharmacokinetics of ciprofloxacin in the elderly.

Authors:  A Bayer; A Gajewska; M Stephens; J M Stark; J Pathy
Journal:  Respiration       Date:  1987       Impact factor: 3.580

3.  Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers.

Authors:  W Brumfitt; I Franklin; D Grady; J M Hamilton-Miller; A Iliffe
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

4.  Novel amino-substituted 3-quinolinecarboxylic acid antibacterial agents: synthesis and structure-activity relationships.

Authors:  M P Wentland; D M Bailey; J B Cornett; R A Dobson; R G Powles; R B Wagner
Journal:  J Med Chem       Date:  1984-09       Impact factor: 7.446

5.  Antibacterial activity of amifloxacin (WIN 49, 375), a new quinolone agent.

Authors:  H C Neu; P Labthavikul
Journal:  Diagn Microbiol Infect Dis       Date:  1985-11       Impact factor: 2.803

Review 6.  Clinical pharmacokinetics of the newer antibacterial 4-quinolones.

Authors:  M Neuman
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

7.  The effect of age on the pharmacokinetics of enoxacin.

Authors:  B R Dobbs; L R Gazeley; A J Campbell; I R Edwards
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.

Authors:  M A Gonzalez; F Uribe; S D Moisen; A P Fuster; A Selen; P G Welling; B Painter
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

9.  The comparative activity of twelve 4-quinolone antimicrobials and sulphadiazine against Neisseria meningitidis.

Authors:  D Felmingham; R A Wall
Journal:  Drugs Exp Clin Res       Date:  1985
  9 in total
  1 in total

1.  Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.

Authors:  Die Cheng; Wei-Ren Xu; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.